Home › Hidradenitis Suppurativa › Alabama › Birmingham
Hidradenitis Suppurativa clinical trials in Birmingham, AL
5 studies for Hidradenitis Suppurativa are looking for participants at sites in and around Birmingham (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
RecruitingPhase 2
- Oruka Therapeutics Investigative Site, Birmingham
Regulation of Inflammatory Genes in Hidradenitis Suppurativa
RecruitingObservational study
- Whitaker Clinic, Birmingham
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
RecruitingPhase 3
- Investigative Site US106, Birmingham
- Investigative Site US086, Birmingham
Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
RecruitingEarly phase 1
- University of Alabama at Birmingham, Birmingham
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RecruitingPhase 2
- University of Alabama At Birmingham, Birmingham
About Hidradenitis Suppurativa
Hidradenitis suppurativa (HS), or acne inversa, is a chronic skin disease. It causes painful bumps in your armpits and groin. Learn about treatment.
More about Hidradenitis Suppurativa on MedlinePlus
Hidradenitis Suppurativa trials in other cities
- Boston, MA9 studies
- Tampa, FL7 studies
- Miami, FL6 studies
- New York City, NY5 studies
- Dallas, TX5 studies
- Phoenix, AZ5 studies
- New Orleans, LA4 studies
- Santa Clarita, CA4 studies
- Scottsdale, AZ4 studies
- Durham, NC4 studies
- Minneapolis, MN4 studies
- Philadelphia, PA4 studies
Other studies in Birmingham
- Cancer (all types)31 studies
- Breast Cancer24 studies
- Ovarian Cancer23 studies
- Obesity23 studies
- Non-Small Cell Lung Cancer22 studies
- Acute Myeloid Leukemia21 studies
- Multiple Myeloma18 studies
- COPD17 studies
- Cardiovascular Disease17 studies
- Type 2 Diabetes16 studies
- Endometrial Cancer16 studies
- Overweight16 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.